SES
10.4.2018 18:02:11 CEST | Business Wire | Press release
Following major space and ground infrastructure investments and the expansion of its Latin America video neighbourhood, SES today announced the launch of its Ultra HD platform into the region to accelerate commercial 4K rollouts among leading cable, IPTV, and DTH providers across Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006195/en/
Many of Latin America’s leading Pay TV providers are already testing SES’s new Ultra HD solution, an all-in-one package of pre-configured Ultra HD content, reception equipment, and satellite distribution that will enable quick and easy Ultra HD deployments over the region. The new SES Latin America Ultra HD solution will open with four Ultra HD channels, including NASA TV UHD, produced by Harmonic, as well as the SES Ultra HD demo channel, an incubator for emerging 4K content producers. SES plans to add new channels and content produced in Brazil, Mexico, and other Latin American countries in the future.
Like SES’s North America Ultra HD solution, the end-to-end Latin America platform will be distributed over multiple SES satellites. SES-6 will provide dedicated delivery across 100% of the Brazilian market, offering programming flexibility for local content. SES’s NSS-806 satellite, home to SES’s leading Latin American Pay TV neighbourhood, will serve the rest of the region until it is replaced by the recently launched SES-14 satellite later this year. Once SES-14 initiates service, SES plans to significantly expand the Latin America channel lineup on its expanding video neighbourhood at 47.5 West. SES is the unmatched leader in global HD and Ultra HD distribution, and has experienced unprecedented 18% year-on-year growth in Latin America with over 300 HD and Ultra HD channels currently hosted on its satellites.
“SES is ushering in an exciting new era of advanced television services across the region with the launch of our new Latin America Ultra HD platform – the latest game-changing solution built on SES’s robust network of space and ground infrastructure. The SES network is enabling the efficient delivery of HD, Ultra HD, and OTT content to audiences throughout the region,” said Jurandir Pitsch, Vice President, Sales and Market Development for SES Video in Latin America and the Caribbean. “Latin America’s leading Pay TV providers are poised to offer Ultra HD content to their subscribers via the SES platform ahead of the 2018 World Cup, which is driving strong interest in 4K services across the region.”
The SES-backed antenna programme, which led to the installation of satellite antennas at Pay TV distribution hubs throughout Latin America, puts SES in a prime position to help cable, IPTV and DTH providers reach 100% of the region’s vast audiences with advanced HD and Ultra HD content.
Learn more about the SES UHD platform
Follow us on:
About SES
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 16 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006195/en/
Contact:
SES
Markus Payer
Corporate Communications & PR
Tel.
+352 710 725 500
Markus.Payer@ses.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom